Jul 1, 2009
By:Wayne Kuznar
Data from a large registry of men with localized prostate cancer suggest better outcomes for radical prostatectomy compared to other therapies when either cancer-specific or overall mortality is the outcome.
 |
Roundtable also calls for greater support of young scientists
Jun 1, 2009
By:Bob Gatty
Prostate cancer research deserves the same level of government commitment that other forms of cancer receive, even those that affect young children.
|
Jun 1, 2009
By:Wayne Kuznar
Dutasteride (Avodart) reduces the risk of biopsy-detectable prostate cancer by about one-fourth in men at high risk for the disease without increasing the risk of high-grade cancers. In addition, the 5-alpha-reductase inhibitor significantly enhances the utility of PSA as a diagnostic test for prostate cancer.
|
Jun 1, 2009
By:Richard R. Kerr
Results of a milestone study on the use of an experimental form of immunotherapy may usher in a new era in the management of androgen-independent prostate cancer.
|
Jun 1, 2009
By:J. Brantley Thrasher, MD
Further analysis of the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial will help answer important questions and direct therapy.
|
Apr 26, 2009
Ferring Pharmaceuticals' novel treatment for advanced prostate cancer, degarelix, is available for use.
|
Studies needed to determine digoxin dosage with antitumor efficacy, safety in humans
Apr 15, 2009
By:Cheryl Guttman
Findings from a series of preclinical studies show that digoxin (Lanoxin) can affect tumor biology and interfere with tumor growth and may provide a basis for conducting clinical trials to investigate a potential role of the drug in prostate and other cancers, said Gregg L. Semenza, MD, PhD.
|
Findings suggest that DNA testing in early-stage patients could help guide management
Apr 15, 2009
By:Cheryl Guttman
Results of a community-based case-control study show that men with prostate cancer carrying BRCA1 and BRCA2 founder mutations have an increased susceptibility to having advanced disease.
|
Sarcosine level may become focus for disease detection, progression, treatment
Apr 1, 2009
By:Cheryl Guttman
Using a relatively novel approach to identify microalterations differentiating benign prostatic disease from clinically localized prostate cancer and its progression to metastatic disease, researchers at the University of Michigan have identified a series of metabolites that they believe hold promise for use as biomarkers of tumor aggressiveness and invasiveness.
|
| 
Brings you the latest news and information twice each month.
Urology Times archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.